Fresenius SE & Co KGaA (FRE) Given a €71.00 Price Target by Goldman Sachs Analysts

Fresenius SE & Co KGaA (FRA:FRE) has been given a €71.00 ($87.65) price objective by research analysts at Goldman Sachs in a research report issued to clients and investors on Monday. The firm currently has a “neutral” rating on the stock. Goldman Sachs’ target price indicates a potential upside of 7.97% from the company’s previous close.

Several other brokerages have also commented on FRE. Commerzbank set a €79.00 ($97.53) price target on Fresenius SE & Co KGaA and gave the company a “buy” rating in a research note on Monday. Berenberg Bank set a €88.10 ($108.77) price target on Fresenius SE & Co KGaA and gave the company a “buy” rating in a research note on Monday. Nord/LB set a €82.00 ($101.23) price target on Fresenius SE & Co KGaA and gave the company a “buy” rating in a research note on Tuesday, February 27th. Independent Research set a €78.00 ($96.30) price target on Fresenius SE & Co KGaA and gave the company a “buy” rating in a research note on Tuesday, February 27th. Finally, Deutsche Bank set a €83.00 ($102.47) price target on Fresenius SE & Co KGaA and gave the company a “buy” rating in a research note on Monday, January 22nd. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the company. Fresenius SE & Co KGaA has a consensus rating of “Buy” and a consensus price target of €77.69 ($95.91).

Shares of Fresenius SE & Co KGaA stock opened at €65.76 ($81.19) on Monday. Fresenius SE & Co KGaA has a 12 month low of €60.16 ($74.27) and a 12 month high of €80.00 ($98.77).

COPYRIGHT VIOLATION NOTICE: This report was published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://transcriptdaily.com/2018/04/23/fresenius-se-71-00-price-target-by-goldman-sachs-analysts.html.

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply